A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Published:2018-09 Issue:9 Volume:29 Page:1895-1902
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mateo J.^ORCID,Chakravarty D.,Dienstmann R.^ORCID,Jezdic S.,Gonzalez-Perez A.,Lopez-Bigas N.,Ng C.K.Y.,Bedard P.L.,Tortora G.,Douillard J.-Y.,Van Allen E.M.,Schultz N.,Swanton C.,André F.^ORCID,Pusztai L.

Funder

The Scale of Actionability

European Society for Medical Oncology

Bristol-Myers Squibb

Sanofi

AstraZeneca

Genentech

Roche

SERVIER

GlaxoSmithKline

Novartis

SignalChem

PTC Therapeutics

Nektar

Merck

Seattle Genetics

AIRC

The Francis Crick Institute

MRC

Wellcome Trust

Cancer Research UK

TRACERx

CRUK Cancer Immunotherapy Catalyst Network

CRUK Lung Cancer Centre of Excellence

Stand Up 2 Cancer

SU2C

Rosetrees and Stoneygate Trusts

NovoNordisk Foundation

NIHR

BRC

University College London Hospitals

CRUK University College London Experimental Cancer Medicine Centre

Breast Cancer Research Foundation

UCLH Biomedical Research Council

Rosetrees Trust

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/9/1895/25845239/mdy263.pdf

Reference42 articles.

1. Implementing genome-driven oncology;Hyman;Cell,2017

2. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients;Zehir;Nat Med,2017

3. Limits to personalized cancer medicine;Tannock;N Engl J Med,2016

4. Marketing personalized cancer treatments requires careful language;Nature,2018

5. Prioritizing targets for precision cancer medicine;Andre;Ann Oncol,2014

Cited by 490 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2;Pathology - Research and Practice;2024-10

2. Assessing actionability and incidental findings of germline variants in two precision oncology trials;European Journal of Cancer;2024-10

3. Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility;Nature Communications;2024-09-04

4. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer;Critical Reviews in Oncology/Hematology;2024-09

5. Comparison of Results from Two Commercially Available In-House Tissue-Based Comprehensive Genomic Profiling Solutions;The Journal of Molecular Diagnostics;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3